Nijmegen, The Netherlands – March 3, 2010 – Syntarga B.V., the emerging
Antibody-Drug Conjugate (ADC) company, announces today that it entered into research
collaborations with two undisclosed top-15 pharma companies. These latest agreements,
adding to a total of five collaborations with top-15 biopharma companies, exemplify the
growing interest in Syntarga’s Potent Payload technology to empower anticancer
antibodies.
Lack of efficacy of unconjugated (naked) antibodies is a problem in oncology. Syntarga
Potent Payload Technology combines extremely potent, proprietary duocarmycin toxins,
a class of DNA minor groove binding agents, with unique, proprietary linker technologies.
The company has generated a strong biological data package for its synthetic Linker-
Drug payloads conjugated to various antibodies against a variety of tumor targets,
including Trastuzumab/Her2.
Under the scope of the two research collaborations, ADCs will be evaluated based on
various Linker-Drug chemistries and a variety of antibodies. Based on ongoing
discussions, the company is optimistic that research collaborations will be started with a
number of additional top-tier biopharma companies in the near future.
Syntarga has only recently achieved the current Proof of Concept status for its latest
generation of ADC chemistries. "These collaborations illustrate the strength of the Potent
Payload preclinical data and underscore the increasing interest of major biopharma
players in our proprietary ADC technology" said Dr. Vincent de Groot, Chief Executive
Officer of Syntarga.
About Syntarga BV
Syntarga is a privately held biopharmaceutical company engaged in the discovery and
development of proprietary Antibody-Drug Conjugate technology and products for the
treatment of cancer. The Company's cutting-edge chemistry capabilities and unique
know-how have led to the creation of its antibody empowering Potent Payload
Technology. Syntarga is leveraging its proprietary technologies and expertise to generate
and commercialize, alone and with partners, a portfolio of next generation Antibody-Drug
Conjugate products. For more information about Syntarga, visit its website at
www.syntarga.com.
